Results 41 - 50 of 258 : Previous 1 2 3 4 5 6 7 8 9 Next
Me-Too Drugs: Are They Worth It?
These drugs have less risk, but also usually bring less of a reward.
Lipitor Marketing Raises Blood Pressure
Pfizer continues affinity-group marketing of its best-selling cholesterol drug
The health-care conglomerate is cutting jobs in its diagnostic testing division.
Don't Worry About Vytorin's Cancer Risk
Congress' ramblings are much ado about nothing.
Johnson & Johnson Gets Rejected
The FDA rejects Johnson & Johnson's antibiotic.
Uh-oh. Merck's HPV vaccine may not be cost-effective.
Expanding the market for its hepatitis C drug could pay off richly for Vertex.
Eli Lilly buys Monsanto's cow hormone business.
Now you can grab some solid performers that are open to new investors again.
Comparing Berkshire Hathaway to mutual funds and ETFs is problematic.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK